Control of excipient manufacturing and distribution, and meeting the appropriate GMP and GDP requirements, has become ; In order to guarantee the quality and safety of novel excipients and delivery systems, the corresponding risk control and mitigation strategies must be created in order to meet acceptance criteria. The regulatory constraints, including the lack of the established approval pathways, are continuing to be a problem in accelerating of excipients innovation.